Gene Signal
International Headquarters
Chemin des Planchamps, 32
Epalinges
1066
Tel: 41-21-8046164
Fax: 41-21-8046165
Website: http://www.genesignal.com/
Email: ev@genesignal.com
5 articles about Gene Signal
-
Gene Signal Announces Positive Data From Phase 3 Trial of Aganirsen Eye Drops For Corneal Neovascularisation Due To Inflammation, A Rare Eye Disease With European Orphan Drug Designation
5/14/2014
-
Gene Signal and Collaborators Demonstrate Successful Activity of Topical Aganirsen in Models of Retinal Neovascular Disease
2/14/2012
-
Gene Signal and Collaborators Publish GS-101 Phase II Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth
9/1/2009
-
Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 for Diseases of the Eye
8/11/2009
-
Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
11/10/2008